Cytokinetics CYTK Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's short-term investments?
- Cytokinetics (CYTK) reported short-term investments of $688.71M in Q1 2026.
- How has Cytokinetics's short-term investments changed year-over-year?
- Cytokinetics's short-term investments decreased by 20.3% year-over-year, from $864.54M to $688.71M.
- What is the long-term trend for Cytokinetics's short-term investments?
- Over 5 years (2020 to 2025), Cytokinetics's short-term investments has grown at a 14.8% compound annual growth rate (CAGR), from $381.08M to $759.7M.
- What does short-term investments mean?
- Financial investments that the company expects to convert into cash within one year.
- How do you interpret short-term investments?
- An increase indicates the company is parking excess cash in interest-bearing instruments, while a decrease may signal the liquidation of assets to fund operations.
- How does short-term investments compare across companies?
- Commonly used by R&D-heavy companies to manage cash reserves; peers often hold significant portions of their balance sheet in these instruments.